Age, Gender, and Body Mass Index as Determinants of Surgical Outcome in Primary Aldosteronism

Abstract

Although unilateral primary aldosteronism (PA) should be curable by adrenalectomy (ADX), postsurgical outcome is affected by several clinical factors. Herein we reviewe the importance of age, gender, and BMI as determinants of surgical success based on the recent findings including a nation-wide, multicenter study in Japan (JPAS/JRAS). It is important to determine whether ADX for elderly patients with unilateral PA is as beneficial as younger patients. JPAS/JRAS showed that ADX could benefit elderly patients (>65 years) with definitive unilateral PA in curing of disease and improvement of hypertension, although potential adverse outcomes including hyperkalemia and renal insufficiency need to be considered in some elderly patients at high risk. As shown in previous studies, JPAS/JRAS also demonstrated that female gender was an independent predictor for clinical cure after ADX in patients with unilateral PA. The gender-specific predominance of somatic mutations of aldosterone-producing adenoma and sex hormones with vasculo-protective effects might account for the difference of surgical outcome between genders. Additionally, lower body mass index (BMI) has been shown to be one of the predictive factors for better clinical outcome after ADX. The relation between BMI and surgical outcome is, however, independent from aldosterone, since BMI does not correlate with PAC in PA. Early diagnosis of PA and lifestyle modification including weight control are essential to improve the surgical outcome of the unilateral PA. Thus, clinical practice guideline should include sophisticated strategy of ADX considering not only subtype diagnosis by adrenal venous sampling but also age, gender, and BMI to predict better surgical outcome.

Key words

aldosterone - adrenalectomy - gender-specific - elderly patients - obesity

Publication History

Received: 02 December 2019

Accepted: 09 March 2020

Article published online:
06 April 2020

• References

• 1 Vaidya A, Mulatero P, Baudrand R. et al. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev 2018; 39: 1057-1088
• 2 Ohno Y, Sone M, Inagaki N. et al. Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: A multicenter study in Japan. Hypertension 2018; 71: 530-537
• 3 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 4 Katabami T, Fukuda H, Tsukiyama H. et al. Clinical and biochemical outcomes after adrenalectomy and medical treatment in patients with unilateral primary aldosteronism. J Hypertens 2019; 37: 1513-1520
• 5 Williams TA, Lenders JWM, Mulatero P. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet Diabetes Endocrinol 2017; 5: 689-699
• 6 Takeda M, Yamamoto K, Akasaka H. et al. Clinical characteristics and postoperative outcomes of primary aldosteronism in the elderly. J Clin Endocrinol Metab 2018; 103: 3620-3629
• 7 Burrello J, Burrello A, Stowasser M. et al. The primary aldosteronism surgical outcome score for the prediction of clinical outcomes after adrenalectomy for unilateral primary aldosteronism. Ann Surg. 2019 [Epub ahead of print].
• 8 Morisaki M, Kurihara I, Itoh H. et al. Predictors of clinical success after surgery for primary aldosteronism in the Japanese Nationwide Cohort. J Endocr Soc 2019; 3: 2012-2022
• 9 Fischer E, Hanslik G, Pallauf A. et al. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab 2012; 97: 3965-3973
• 10 Park KS, Kim JH, Ku EJ. et al. Clinical risk factors of postoperative hyperkalemia after adrenalectomy in patients with aldosterone-producing adenoma. Eur J Endocrinol 2015; 172: 725-731
• 11 Wada N, Shibayama Y, Umakoshi H. et al. Hyperkalemia in both surgically and medically treated patients with primary aldosteronism. J Hum Hypertens 2017; 31: 627-632
• 12 Kobayashi H, Abe M, Nakamura Y. et al. Association between acute fall in estimated glomerular filtration rate after treatment for primary aldosteronism and long-term decline in renal function. Hypertension 2019; 74: 630-638
• 13 Zarnegar R, Young WF, Lee J. et al. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg 2008; 247: 511-518
• 14 Akasaka H, Yamamoto K, Rakugi H. et al. Sex difference in the association between subtype distribution and age at diagnosis in patients with primary aldosteronism. Hypertension 2019; 74: 368-374
• 15 Choi M, Scholl UI, Yue P. et al K+channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science 2011; 331: 768-772
• 16 Williams TA, Monticone S, Mulatero P. KCNJ5 mutations are the most frequent genetic alteration in primary aldosteronism. Hypertension 2015; 65: 507-509
• 17 Zheng FF, Zhu LM, Nie AF. et al Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma. Hypertension 2015; 65: 622-628
• 18 Kitamoto T, Suematsu S, Matsuzawa Y. et al. Comparison of cardiovascular complications in patients with and without KCNJ5 gene mutations harboring aldosterone-producing adenomas. J Atheroscler Thromb 2015; 22: 191-200
• 19 Taguchi R, Yamada M, Nakajima Y. et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab 2012; 97: 1311-1319
• 20 Vilela LAP, Rassi-Cruz M, Guimaraes AG. et al KCNJ5 somatic mutation Is a predictor of hypertension remission after adrenalectomy for unilateral primary aldosteronism. J Clin Endocrinol Metab 2019; 104: 4695-4702
• 21 Fernandes-Rosa FL, Williams TA, Riester A. et al. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension 2014; 64: 354-361
• 22 Saiki A, Otsuki M, Mukai K. et al. Basal plasma aldosterone concentration predicts therapeutic outcomes in primary aldosteronism. J Endocr Soc. 2020
• 23 Tuck ML, Sowers J, Dornfeld L. et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 1981; 304: 930-933
• 24 Engeli S, Böhnke J, Gorzelniak K. et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005; 45: 356-362
• 25 Rocchini AP, Katch VL, Grekin R. et al. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol 1986; 57: 613-618
• 26 Huby AC, Antonova G, Groenendyk J. et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 2015; 132: 2134-2145
• 27 Fallo F, Veglio F, Bertello C. et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 454-459
• 28 Rossi GP, Belfiore A, Bernini G. et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008; 93: 2566-2571
• 29 Somloova Z, Widimsky J, Rosa J. et al. The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. J Hum Hypertens 2010; 24: 625-630
• 30 Matrozova J, Steichen O, Amar L. et al. Fasting plasma glucose and serum lipids in patients with primary aldosteronism: a controlled cross-sectional study. Hypertension 2009; 53: 605-610
• 31 Ohno Y, Sone M, Inagaki N. et al. Obesity as a key factor underlying idiopathic hyperaldosteronism. J Clin Endocrinol Metab 2018; 103: 4456-4464
• 32 Adolf C, Asbach E, Dietz AS. et al. Worsening of lipid metabolism after successful treatment of primary aldosteronism. Endocrine 2016; 54: 198-205
• 33 Akehi Y, Yanase T, Motonaga R. et al. High prevalence of diabetes in patients with primary aldosteronism (PA) associated with subclinical hypercortisolism and prediabetes more prevalent in bilateral than unilateral PA: A large, multicenter Cohort study in Japan. Diabetes Care 2019; 42: 938-945
• 34 Omata K, Satoh F, Morimoto R. et al. Cellular and genetic causes of idiopathic hyperaldosteronism. Hypertension 2018; 72: 874-880
• 35 Bokuda K, Yatabe M, Mizuguchi Y. et al. Body mass index and contralateral ratio predict outcome following unilateral adrenalectomy in primary aldosteronism. Hypertens Res 2017; 40: 988-993